Visit specialist site

Ryan Smith

Founder and Global Head of Research & Development · TruDiagnostic

Biochemist-operator leading TruDiagnostic's R&D, methylation algorithms, trials, and research partnerships

Ryan Smith portrait

About

Ryan Smith founded TruDiagnostic in 2020 and leads its research and development work: methylation algorithms, the clinical-trial pipeline, and university research collaborations. He studied biochemistry and philosophy at Transylvania University, entered the University of Kentucky College of Medicine, completed two years, passed USMLE Step 1, and left during clinicals to build biomedical companies. His first major venture was Tailor Made Compounding, a Lexington peptide-synthesis pharmacy that scaled to roughly $80M in revenue within three years before his 2020 exit.

What to Know

Signature approach

Smith's R&D work centers on turning methylation data into usable algorithms. TruDiagnostic's platform reads signals such as inflammatory markers, telomere length, aging pace, immune-cell subsets, and cellular replication from DNA methylation patterns, then tests those signals through a 30+ trial portfolio and collaborations with Duke, Harvard, Yale, UCSF, and Ohio State.

What sets them apart

  • Biochemistry-to-company path. Smith built Tailor Made Compounding first, then carried peptide and cash-pay wellness market experience into methylation diagnostics.
  • Education-circuit footprint. A4M, the International Peptide Society, ACAM, and Age Management Medical Group place him in the practitioner-training world around peptides and longevity medicine.
  • Research-database scale. TruDiagnostic's EPIC850k methylation dataset is the substrate for the company's algorithm work and a major commercial research asset.

Affiliations

Founder

Lexington, KY

Thought Leadership

Other specialists at TruDiagnostic

Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.